Bingnan Zhang, MD, MBA
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Zhang’s research interests involve studying biomarkers, lineage plasticity, and novel therapies to treat lung cancers. She has been conducting research to identify biomarkers and cell surface targets in small cell lung cancer (SCLC), including SCLC transformation from non-small cell lung cancer as a resistance mechanism. She also works on bringing new therapies to patients through clinical trials and translational research.
Clinical Interests
Dr. Zhang is a medical oncologist dedicated to improving the outcomes of patients with thoracic malignancies. Her work focuses on bringing the most effective, personalized treatment to individual patients, both through standard-of-care options and clinical trials. She also works closely with a multidisciplinary team, including thoracic surgeons and radiation oncologists, to deliver the highest quality care.
Education & Training
Degree-Granting Education
| 2014 | Yale School of Management, New Haven, Connecticut, US, Business administration, MBA |
| 2014 | Yale School of Medicine, New Haven, Connecticut, US, MD |
| 2009 | McGill University, Montreal, CA, Microbiology and Immunology, BS |
Postgraduate Training
| 2020-2023 | Hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2017 | Medicine Residency, University of California Los Angeles, Los Angeles, California |
Licenses & Certifications
| 2024 | American Board of Internal Medicine |
| 2019 | Texas Medical Board |
| 2017 | Medical Board of California |
| 2017 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Clinical Specialist - Hospitalist, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Clinical Instructor - Hospitalist, Department of Medicine, University of California Los Angeles, Los Angeles, CA, 2017 - 2019
Administrative Appointments/Responsibilities
Associate Medical Director, Inpatient Services, Department of Medicine, University of California Los Angeles, Los Angeles, California, 2018 - 2019
Physician Informaticist, University of California Los Angeles, Los Angeles, California, 2018 - 2019
Editorial Activities
Member of Editorial Review Board, Therapeutic Advances in Medical Oncology, 2023 - Present
Honors & Awards
| 2026 - Present | Awardee, IASLC (International Association for the Study of Lung Cancer) Academy |
| 2026 - Present | Awardee, Leading Clinical Research Faculty Learning Series |
| 2023 | 1st place winner of Fellows’ poster competition, Texas Lung Cancer Conference |
| 2021 | Jeffrey Lee Cousins Endowed Fellowship in Lung Cancer Research |
| 2015 | Commendation for Excellence in Medical Student Teaching UCLA |
| 2012 - 2014 | Yale School of Management merit-based scholarship |
| 2012 | Inaugural Yale Global Health Case Competition Grand Winner |
| 2010 | NIH Research Education Fellowship |
| 2008 | McGill University Meakins-Christie Laboratories scholarship |
| 2007 - 2009 | Golden Key International Honor Society, McGill Chapter |
| 2007 - 2009 | James McGill Scholarship |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Tarlatamab and other DLL3 T cell engagers: experience and ongoing research at MD Anderson. Invited. Department of Internal Medicine Grand Rounds. Houston, Texas, US.
- 2025. Rapid intracranial response with tarlatamab in patients with untreated brain metastases from small cell lung cancer in SCLC section. Invited. 2025 Annual lung Spore Meeting. Houston, Texas, US.
- 2025. Rapid intracranial response with tarlatamab in patients with untreated brain metastases from small cell lung cancer – a real world case series. Invited. Brain Metastasis Research Retreat. Houston, Texas, US.
- 2025. MDA Cancer Network Thoracic Integration Research Presentation. Invited. Houston, Texas, US.
National Presentations
- 2026. DLL3 - CAR T in SCLC/LCNEC: LB2102. Invited. 5th Global Summit on Thoracic Malignancies. Kona, Hawaii.
- 2026. Tris-specific DLL3 T cell engager in SCLC and NEC. Invited. 5th Global Summit on Thoracic Malignancies. Kona, Hawaii.
- 2026. Alveltamig (ZG006); 3) alpha 225Ac –radioligand therapy in SCLC. 5th Global Summit on Thoracic Malignancies. Kona, Hawaii.
- 2026. Tarlatamab in relapsed/refractory SCLC. Invited. 5th Global Summit on Thoracic Malignancies. Kona, Hawaii.
- 2026. Bi/tri-specific T cell engagers in small cell lung cancer. Invited. Tuscon Symposium. Tucson, US.
- 2026. 2026 Targeted Therapies of Lung Cancer Meeting. Invited. 2026 Targeted Therapies of Lung Cancer Meeting. Huntington Beach, California, US.
- 2025. Emerging Roles of ADCs and Biospecifics in CNS Metastases. Invited. 2025 SNO/ASCO CNS Metastases Conference. Baltimore, MA, US.
- 2025. Texas Lung Conference. Invited. IASLC 2025 Texas Lung Conference. Austin, TEXAS, US.
- 2024. Activity of HER2-and TROP2- antibody drug conjugates (ADCs) in small cell lung cancer (SCLC) models with SLFN11 as a predictive biomarker. Poster. AACR Annual Meeting 2024. San Diego, CA, US.
- 2024. Targeted therapies: ADCs and novel targets (no ERBB or MET), DLL3/CD56 (SCLC). IASLC TTLC (Targeted Therapies of Lung Cancer) Meeting. Santa Monica, CA, US.
- 2023. Novel surface targets for CAR-T in SCLC. Invited. 2023 Hawaii Lung-2nd Global Summit on Thoracic Malignancies. Kona, HI, US.
- 2023. Lineage plasticity in EGFR-NSCLC transformation to SCLC. Invited. 2023 Hawaii Lung-2nd Global Summit on Thoracic Malignancies. Kona, HI, US.
Grant & Contract Support
| Date: | 2026 - 2027 |
| Title: | K12 Calabresi Scholars Program |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Trainee |
| ID: | K12CA088084 |
| Date: | 2026 - 2027 |
| Title: | Predicting tarlatamab response and resistance through artificial intelligence (AI) radiomics in patients with small cell lung cancer |
| Funding Source: | Rexanna’s foundation for Fighting Lung Cancer |
| Role: | PI |
| Title: | Harnessing DLL3 as a CAR T target in small cell lung cancer |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | PI |
| ID: | AWD00007208 |
Selected Publications
Peer-Reviewed Articles
- Tanimoto, A, Ramkumar, K, Stewart, CA, Zhang, B, Concannon, KF, Cardnell, R, Shen, L, Wang, Q, Wang, J, Gay, CM, Byers, LA. The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC–High SCLC. Journal of Thoracic Oncology 21(5), 2026. e-Pub 2026. PMID: 41456708.
- Stewart CA, Ramkumar K, Wang R, Xi Y, Halliday A, Diao L, Wang Q, Serrano A, Groves S, Heeke S, Tanimoto A, Kaiser L, Lewis W, Bose M, Da Rocha P, Karacosta L, Quaranta V, Wang J, George J, Solis Soto LM, Zhang B, Heymach JV, Byers LA, Gay CM. YAP1 defines an emergent, plastic population of relapsed small cell lung cancer. J Thorac Oncol:103730, 2026. e-Pub 2026. PMID: 42019833.
- Parma, M, Wang, K, Taslicay, CA, Shah, K, Singhi, EK, Rivera, MJ, Solis Soto, LM, Wang, W, Hong, L, Li, Z, Altan, M, Franco Vega, M, de Groot, P, Halliday, A, Jacome, J, Zhang, J, Le, X, Pozadzides, JV, Tu, J, Bueno Hume, C, Blumenschein, GR, Skoulidis, F, Cascone, T, Fossella, FV, Vailati Negrao, M, Vokes, N, Gibbons, DL, Araujo, HA, Tsao, A, Heymach, JV, Byers, LA, Gay, CM, Zhang, B. Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity. JCO Precision Oncology 10, 2026. e-Pub 2026. PMID: 42024839.
- Wang, K, Taslic, CA, de Groot, P, Parma, M, Paula, AG, Caranto, M, Shah, K, Bose, M, Ruoff, C, Karacosta, LG, Byers, LA, Gay, CM, Zhang, J, Heymach, JV, Zhang, B. First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC. JTO Clinical and Research Reports 7(2), 2026. e-Pub 2026. PMID: 41584719.
- Zhang, B, Alder, L, Rosner, S, Desai, A, Cooper, AJ, Yimer, HA, Bogdanska, W, Naqash, AR, Taylor, A, Joshi, U, Carlisle, JW, Champiat, S, Altan, M, Vega, MF, Halm, J, Manzano, JM, Fenton, G, Nie, Y, Wang, K, Parma, M, Rudin, CM, Chiang, A, Byers, LA, Gay, CM, Puri, S. A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS. Lung Cancer 211, 2026. e-Pub 2026. PMID: 41371100.
- Li, H, Hong, L, Rocha, P, Bach, R, Solis Soto, LM, Rinsurongkawong, W, Zhang, B, Araujo, HA, Elamin, YY, Altan, M, Arrechedera, C, Zhou, J, Khan, KB, Lu, W, Young, E, Gay, CM, Cascone, T, Byers, LA, Skoulidis, F, Blumenschein, GR, Fossella, FV, Tsao, A, Vailati Negrao, M, Vokes, N, Wu, J, Tran, HT, Wistuba, II, Lee, JJ, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Le, X, Zhang, J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers 17(23), 2025. e-Pub 2025. PMID: 41375002.
- Stewart DJ, Zhang B, Kurzrock R. Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report. Lung Cancer 210:108844, 2025. e-Pub 2025. PMID: 41260046.
- Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol 9:e2500538, 2025. e-Pub 2025. PMID: 41166675.
- Zhang, B, Shah, K, Parma, M, Wang, K, Singhi, EK, Lewis, WE, Rivera, MJ, Altan, M, Pozadzides, JV, Le, X, Vokes, N, Fossella, FV, O'Brien, BJ, Wang, C, Tom, MC, Beckham, TH, Swanson, T, Bronk, JK, Lin, SH, Vega, MF, Jacome, J, Halliday, A, Vailati Negrao, M, Zhang, J, Gibbons, DL, Heymach, JV, Byers, LA, Gay, CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series. Journal of Thoracic Oncology 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
- Li H, Salehjahromi M, Godoy MCB, Qin K, Plummer CM, Zhang Z, Hong L, Heeke S, Le X, Vokes N, Zhang B, Araujo HA, Altan M, Wu CC, Antonoff MB, Ostrin EJ, Gibbons DL, Heymach JV, Lee JJ, Gerber DE, Wu J, Zhang J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361426.
- Serrano, A, Rocha, P, Freitas Lima, C, Stewart, A, Zhang, B, Diao, L, Fujimoto, J, Cardnell, R, Lu, W, Khan, KB, Sable, B, Ellison, AR, Wistuba, II, Concannon, KF, Halperin, DM, Czerniak, BA, Sircar, K, Zhang, M, Cargill, KR, Wang, Q, Aparicio, A, Lazar, A, Hernandez, S, Estrella, JS, Ramalingam, P, El-Naggar, AK, Kalhor, N, Gay, CM, Byers, LA, Solis Soto, LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39558076.
- Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A Jr, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res 30(20):4743-4754, 2024. e-Pub 2024. PMID: 39150543.
- Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horvath I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42(2):225-237.e5, 2024. e-Pub 2024. PMID: 38278149.
- Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2024. e-Pub 2024. PMID: 38357092.
- Adimora I, Zhang B, Idowu M. Recurrent Strokes in a Woman with a History of Thrombotic Thrombocytopenic Purpura. Case Rep Med 2023:7070189, 2023. e-Pub 2023. PMID: 37564991.
- Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
- Kundu K, Cardnell RJ, Zhang B, Shen L, Stewart CA, Ramkumar K, Cargill KR, Wang J, Gay CM, Byers LA. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Transl Lung Cancer Res 10(11):4095-4105, 2021. e-Pub 2021. PMID: 35004241.
- Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol 16(11):1821-1839, 2021. e-Pub 2021. PMID: 34274504.
- Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346-360.e7, 2021. e-Pub 2021. PMID: 33482121.
- Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat 175(3):775-779, 2019. e-Pub 2019. PMID: 30847728.
- Zhang B, Master AK, Brown CE, Drakaki A. Not Just Another Infection. Am J Med 131(11):e463-e464, 2018. e-Pub 2018. PMID: 30055122.
- Zhang B, Lee AI, Podoltsev N. Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. Oxf Med Case Reports 2014(8):138-40, 2014. e-Pub 2014. PMID: 25988058.
- Zhang B, Bolognia J, Marks P, Podoltsev N. Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer Chemother Pharmacol 74(2):303-7, 2014. e-Pub 2014. PMID: 24908437.
- Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL. Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk 13(6):716-20, 2013. e-Pub 2013. PMID: 24035715.
Invited Articles
- Zhang B, Birer SR, Dvorkin M, Shruti J, Byers L. New therapies and biomarkers: Are we ready for personalized treatment in small cell lung cancer?. ASCO Education Book, 2021. e-Pub 2021. PMID: 33979194.
Review Articles
- Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Novel therapeutic strategies for recurrent SCLC. Crit Rev Oncol Hematol 186:104017, 2023. e-Pub 2023. PMID: 37150311.
- Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer 125(10):1333-1340, 2021. e-Pub 2021. PMID: 34294893.
- Zhang B, Hurvitz S. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. Clin Adv Hematol Oncol 14(7):520-30, 2016. e-Pub 2016. PMID: 27379947.
- Zhang B, Finn RS. Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer 5(3):221-32, 2016. e-Pub 2016. PMID: 27493897.
- Zhang B, Porto AF. Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr 56(6):682-5, 2013. e-Pub 2013. PMID: 23403440.
Editorials
- Zhang B, Gay CM. Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancer. Transl Lung Cancer Res 14(9):4165-4169, 2025. PMID: 41132950.
- Coleman N, Zhang B, Byers LA, Yap TA. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer 124(5):857-859, 2021. PMID: 33328609.
Abstracts
- Zhang B, Yang Y, Stewart CA, Ramkumar K, Wang R, Cardnell R, Diao L, Wang Q, Wang J, Byers L, Gay C, Heymach J. Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer 83(7):3196, 2023. e-Pub 2023.
- Zhang B, Concannon K, Stewart CA, Lewis W, Xi Y, Cardnell R, Morris BB, Sasaki K, Lopez ER, Rinsurongkawong W, Tran H, Heeke S, Zhang J, Wang J, Heymach JV, Gay CM, Byers LA, Le X. Clinicogenomic characteristics of EGFR mutant non-small cell lung cancer transformation to small cell lung cancer, 2023. e-Pub 2023.
- Heeke S, Gay C, Estecio M, Stewart CA, Tran H, Zhang B, Tang X, Raso G, Concannon K, de Sousa LG, Lewis WE, Nilsson M, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba II, Byers LA, Heymach JV. Use of DNA methylation from tumor and plasma to identify four major small cell lung cancer subtypes with distinct biology and therapeutic vulnerabilities 82(12):3473, 2022. e-Pub 2022.
- Zhang B, Stewart CA, Gay CM, Wang Q, Cardnell R, Fujimoto J, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft J, Jones J, Anderson AK, Wistuba II, Wang J, Wenstrup R, Byers LA. Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum and PARP inhibitor response in small cell lung cancer 81(13):384, 2021. e-Pub 2021.
- Zhang B, Adelson K, Velji S, Rimar J, Longley P, Keane B, Chiang A, Lilenbaum R. Aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital. ASCO Quality Symposium 2014 32(30):S20, 2014. e-Pub 2014.
Book Chapters
- Zhang B, Finn RS. Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies. In: Resistance to Molecular Therapies for Hepatocellular Carcinoma, 133-142, 2017.
Patient Reviews
CV information above last modified August 12, 2026